HK1199211A1 - 流感病毒疫苗及其用途 - Google Patents

流感病毒疫苗及其用途

Info

Publication number
HK1199211A1
HK1199211A1 HK14112786.7A HK14112786A HK1199211A1 HK 1199211 A1 HK1199211 A1 HK 1199211A1 HK 14112786 A HK14112786 A HK 14112786A HK 1199211 A1 HK1199211 A1 HK 1199211A1
Authority
HK
Hong Kong
Prior art keywords
influenza virus
virus vaccines
vaccines
influenza
virus
Prior art date
Application number
HK14112786.7A
Other languages
English (en)
Inventor
Jan Wilem Meijberg
Antonietta Impagliazzo
Ronald Vogels
Robert Heinz Edward Friesen
Philippe Alard
Stefan Loverix
Katarina Radosevic
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of HK1199211A1 publication Critical patent/HK1199211A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
HK14112786.7A 2011-11-28 2014-12-22 流感病毒疫苗及其用途 HK1199211A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564198P 2011-11-28 2011-11-28
US201161564086P 2011-11-28 2011-11-28
EP11191009 2011-11-28
EP11191003 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
HK1199211A1 true HK1199211A1 (zh) 2015-06-26

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112786.7A HK1199211A1 (zh) 2011-11-28 2014-12-22 流感病毒疫苗及其用途

Country Status (20)

Country Link
US (3) US9452211B2 (zh)
EP (2) EP2785372B1 (zh)
JP (1) JP6294828B2 (zh)
KR (1) KR101983989B1 (zh)
CN (1) CN104066446B (zh)
AR (1) AR089005A1 (zh)
AU (1) AU2012343981B2 (zh)
BR (1) BR112014012681A8 (zh)
CA (1) CA2857087C (zh)
EA (1) EA033386B1 (zh)
HK (1) HK1199211A1 (zh)
IL (1) IL232780A (zh)
IN (1) IN2014CN04742A (zh)
MX (1) MX357009B (zh)
MY (1) MY170927A (zh)
PH (1) PH12014501118B1 (zh)
SG (1) SG11201402633UA (zh)
TW (1) TWI618715B (zh)
WO (1) WO2013079473A1 (zh)
ZA (1) ZA201404797B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
EP4241785A3 (en) 2011-09-20 2023-09-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
JP2015519348A (ja) * 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014191435A1 (en) * 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
EP3395826B1 (en) 2013-08-03 2020-10-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
US10344058B2 (en) 2014-05-01 2019-07-09 Indian Institute Of Science Polypeptides for generating anti-influenza antibodies and uses thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA036307B1 (ru) 2014-06-26 2020-10-23 Янссен Вэксинс Энд Превеншн Б.В. Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
PE20170290A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
WO2016005482A1 (en) * 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
BR112017024206A2 (pt) * 2015-05-11 2018-07-17 Janssen Vaccines & Prevention Bv compostos peptidomiméticos neutralizadores do vírus da gripe
JP6975709B2 (ja) 2015-09-02 2021-12-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化したウイルスクラスｉ融合タンパク質
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
KR20190056382A (ko) * 2016-09-02 2019-05-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
US11191825B2 (en) * 2016-09-16 2021-12-07 Vaccitech, Inc. Compositions and methods for vaccination against influenza
WO2018075592A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CA3076263C (en) * 2017-11-22 2023-12-19 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
PT3743106T (pt) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Vacinas contra o vírus da influenza e suas utilizações
KR20220005002A (ko) * 2019-04-25 2022-01-12 얀센 백신스 앤드 프리벤션 비.브이. 재조합 인플루엔자 항원
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
KR20220082042A (ko) * 2019-10-15 2022-06-16 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
US20230310575A1 (en) * 2020-09-02 2023-10-05 St. Jude Children's Research Hospital, Inc. Hemagglutinin Modifications for Improved Influenza Vaccine Production
JP2023539771A (ja) 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
WO2023274860A1 (en) * 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024038382A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. Modified influenza viruses
CN116947982A (zh) * 2023-07-12 2023-10-27 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE60116513T2 (de) 2000-08-10 2006-09-21 Crucell Holland B.V. Adenovirenvektoren zur transduktion der chondrozyten
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
KR101006594B1 (ko) 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2004278517B2 (en) 2003-10-02 2010-04-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2413962A1 (en) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
JP5813629B2 (ja) 2009-05-11 2015-11-17 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ３ｎ２を中和可能なヒト抗体及び／または抗原結合フラグメントおよびその使用
KR20130075732A (ko) * 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
KR101941724B1 (ko) 2011-07-14 2019-01-23 얀센 백신스 앤드 프리벤션 비.브이. 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2900692A1 (en) 2012-09-27 2015-08-05 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
WO2014191435A1 (en) 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
PE20170290A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
WO2016005482A1 (en) 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
EA033386B1 (ru) 2019-10-31
CA2857087A1 (en) 2013-06-06
KR20140099515A (ko) 2014-08-12
PH12014501118A1 (en) 2014-08-04
JP2015502353A (ja) 2015-01-22
AR089005A1 (es) 2014-07-23
CN104066446A (zh) 2014-09-24
PH12014501118B1 (en) 2014-08-04
US20160355553A1 (en) 2016-12-08
EP3566714A1 (en) 2019-11-13
BR112014012681A2 (pt) 2017-06-13
SG11201402633UA (en) 2014-09-26
IN2014CN04742A (zh) 2015-09-18
CN104066446B (zh) 2017-10-03
AU2012343981A1 (en) 2014-07-10
JP6294828B2 (ja) 2018-03-14
EP2785372B1 (en) 2019-06-19
US9969778B2 (en) 2018-05-15
NZ625973A (en) 2016-09-30
CA2857087C (en) 2021-05-25
MX2014006396A (es) 2014-07-22
US20160362455A1 (en) 2016-12-15
IL232780A0 (en) 2014-07-31
MY170927A (en) 2019-09-19
US9452211B2 (en) 2016-09-27
MX357009B (es) 2018-06-22
EP2785372A1 (en) 2014-10-08
AU2012343981B2 (en) 2017-09-07
KR101983989B1 (ko) 2019-05-31
IL232780A (en) 2017-09-28
EA201491051A1 (ru) 2015-04-30
WO2013079473A1 (en) 2013-06-06
ZA201404797B (en) 2022-03-30
TWI618715B (zh) 2018-03-21
BR112014012681A8 (pt) 2017-06-20
TW201329101A (zh) 2013-07-16
US20140357845A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
IL262123A (en) Influenza virus vaccines and their uses
IL261204A (en) Influenza virus vaccines and their use
HK1199211A1 (zh) 流感病毒疫苗及其用途
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
EP2723855A4 (en) MUTANTS OF THE INFLUENZAVIRUS AND ITS USE
HK1223110A1 (zh) 流行性感冒病毒疫苗及其用途
HK1209646A1 (zh) 經鼻流感疫苗組合物
HK1202442A1 (zh) 針對 的疫苗
IL229307A0 (en) Inactivated dengue virus vaccine
PT2806891T (pt) Vacinas baseadas no vírus parainfluenza 5
IL240936B (en) Reassortment of influenza virus and methods for their preparation
PL2935313T3 (pl) Szczepionki przeciwko wirusowi zapalenia wątroby typu b
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
ZA201300395B (en) Influenza vaccine
EP2678043A4 (en) RECOMBINANT MUMPSVIRUS VACCINE
HK1201283A1 (zh) 丙型流感病毒和疫苗
HK1197268A1 (zh) 重組豬流感病毒及其應用